Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of TQB3616 Plus Aromatase Inhibitor in HR-positive HER2-negative Advanced Breast Cancer
ChiCTR2600124423Phase 2Completed
- Sponsor
- Liaoning Province Cancer Hospital
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of culmerciclib in breast cancer (2 arms), sponsored by Liaoning Province Cancer Hospital. Primary endpoint: Objective response rate (ORR). Started May 2026; status: completed.
02
Drugs
culmerciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2600124423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124423.